Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sera Prognostics Q3 2026 Results: Net Loss of $8.05M, Loss Widens

Sera Prognostics, Inc. reported its financial results for the quarter ended September 30, 2026, highlighting continued commercialization efforts for its PreTRM test. The company maintained a strong cash position while focusing on expanding clinical evidence and market adoption to drive long-term growth.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.00.0
Net income-8.1-7.8
EPS (diluted, $ a share)$-0.16$-0.16

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+162.5%
Source

10-Q filed with the SEC, NASDAQ: SERA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sera Prognostics, Inc.: key numbers

Share price
$1.94Close, Nov 16
Sector
Industrial Applications and Services
Industry
Services-Medical LaboratoriesSIC 8071

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sera Prognostics, Inc.

All →
4:11 PM ET 8-K
Financial Results

Sera Prognostics Financial Results

Sera Prognostics reported Q3 2026 financial results, highlighting a 54% sequential increase in PreTRM test volume and a five-fold increase since Q1 2026. The company secured Medicaid coverage for its test in Florida, following a similar win in Illinois, and ended the quarter with $72.8 million in cash and marketable securities.

Term
Q3 2026

“The third quarter marked an important step forward as we continued our transition from evidence generation to commercial execution. We delivered strong growth in physician adoption and test volume, saw expanded reimbursement through a second state Medicaid coverage win in Florida, advanced our commercial payer initiatives, and continued to strengthen our clinical and health economic evidence base.”

Zhenya Lindgardt, President and Chief Executive Officer
5:06 PM ET Form 4
Insider Selling

Sera Prognostics CMO Tiffany Eul Davis Inglis Sells $16.3K of Stock

Tiffany Eul Davis Inglis, CMO, sold 8,024 shares of Sera Prognostics, Inc. at $2.03 a share, worth $16.3K in total on Oct 12, 2026. Shares held after the trade: 83,565 (-8.8%).

Value
$16.3K
Shares
8,024
Price
$2.03
Role
CMO
Holding change
-8.8%
Trade date
Oct 12, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.